For the quarter ending 2025-09-30, WGS had $21,848K increase in cash & cash equivalents over the period. $9,595K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,635 | 4,280 |
| Depreciation and amortization expense | 6,474 | 11,869 |
| Stock-based compensation expense | 10,586 | 11,796 |
| Change in fair value of financial liabilities | 3,401 | -1,081 |
| Deferred tax expense (benefit) | 246 | 202 |
| Provision for excess and obsolete inventory | 29 | 123 |
| Legal reserves | -810 | 0 |
| Change in third party payor reserves | -3,732 | -5,014 |
| Other | 995 | 1,387 |
| Accounts receivable | 12,910 | 9,889 |
| Inventory | -1,332 | 1,404 |
| Accounts payable and accrued expenses | -2,014 | 7,199 |
| Other assets and liabilities | -10,721 | 8,894 |
| Net cash provided by (used in) operating activities | 15,767 | 20,602 |
| Acquisition of business, net of cash acquired | 0 | 33,195 |
| Purchases of property and equipment | 6,172 | 8,498 |
| Purchases of marketable securities | 5,765 | 30,770 |
| Proceeds from sales of marketable securities | 0 | 0 |
| Proceeds from maturities of marketable securities | 7,250 | 26,705 |
| Net cash used in investing activities | -4,687 | -45,758 |
| Proceeds from offerings, net of issuance costs | 11,802 | 13,766 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 0 | 1,262 |
| Exercise of stock options | 182 | 800 |
| Long-term debt principal payments | 304 | 602 |
| Finance lease principal payments | 912 | 1,162 |
| Net cash provided by financing activities | 10,768 | 14,064 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 21,848 | -11,092 |
| Cash and cash equivalents at beginning of period | 86,202 | - |
| Cash and cash equivalents at end of period | 96,958 | - |
GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS)